Agilon Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGL research report →
Range $111 – $146
Price Chart
About the company
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients.
- CEO
- Timothy O'Rourke
- IPO
- 2021
- Employees
- 856
- HQ
- Westerville, OH, US
Get TickerSpark's AI analysis on AGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.52B
- P/E
- -13.78
- Fwd P/E
- 83.43
- PEG
- -0.23
- P/S
- 0.25
- P/B
- 5.40
- EV/EBITDA
- -16.11
- Div Yield
- 0.00%
- Gross Margin
- 2.76%
- Op Margin
- -1.83%
- Net Margin
- -1.77%
- ROE
- -51.95%
- ROIC
- -31.61%
Latest fiscal year · YoY change
- Revenue
- $5.93B-2.1%
- Gross Profit
- $-188,614,999-3996.2%
- Op Income
- $-421,076,000
- Net Income
- $-405,347,000-55.8%
- EPS
- $-24.50-55.6%
- OCF Growth
- -83.1%
- FCF Growth
- -67.5%
- 52W High
- $133.04
- 52W Low
- $7.48
- 50D MA
- $91.75
- 200D MA
- $71.18
- Beta
- 3.11
- RSI (14)
- 41
- Avg Volume
- 226.26K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
agilon beat third-quarter expectations, raised full-year 2026 guidance, and said improving clinical programs and ACO growth are setting up 2027.· November 4, 2026
- Q3 results exceeded guidance across key metrics, prompting a full-year 2026 raise.
- Revenue rose to approximately $1.5 billion, adjusted EBITDA was $64 million, and the medical services expense ratio improved to 88.5%.
- Membership trends were mixed: Medicare Advantage members fell year over year to 454,000, while ACO membership held at 112,000 in the quarter.
- Management said burden-of-illness and clinical pathway programs drove better revenue, while first-half 2026 medical cost trends were favorable.
- The company expects ACO membership to grow about 40%-50% in 2027 and is continuing to roll out clinical pathways, virtual pharmacy, and data/AI tools.
Third-quarter revenue was approximately $1.5 billion, up from $1.4 billion in the third quarter of 2025. Adjusted EBITDA was $64 million versus -$91 million a year ago, and the medical services expense ratio was 88.5% compared with 104% in the prior-year quarter. Medicare Advantage membership was 454,000 versus 503,000 in Q3 2025, and ACO membership was 112,000 versus 115,000 a year ago. For full-year 2026, management now expects revenue of approximately $5.88 billion, MSER of 90.4%, and Adjusted EBITDA of approximately $150 million; ACO REACH Adjusted EBITDA is expected to be $40 million-$45 million. The company also raised its year-end 2026 cash outlook to at least $175 million, from $312 million in cash and marketable securities at quarter-end, plus $74 million of off-balance-sheet cash held by ACO entities.
Tim O'Rourke framed the quarter as proof that agilon’s operational discipline and clinical model are improving execution. He emphasized earlier identification of high-risk patients, stronger care coordination, and the company’s use of data and technology to make its value-based care model more scalable and resilient. He was optimistic about ACO growth, saying existing and prospective physician interest is strong and that the business is positioned for meaningful impact in 2027 and beyond.
Jeff Schwaneke said Q3 performance was driven by better-than-expected burden-of-illness and clinical pathway results, plus favorable first-half 2026 cost trends. He quantified several drivers of the EBITDA beat, including $14 million of favorable prior-year development, $23 million from revised risk adjustment, $11 million from ACO performance, and $12 million from favorable first-half cost trends, with about $4 million of timing-related expense shifting into Q4. He also said first-half 2026 cost trend was estimated in the low 6% range, Q3 cost trend was in the low 7% range, and full-year guidance assumes 7% cost trend for the rest of the year.
Analysts focused on three areas: the timing of new market growth, the sustainability of cost trends, and the ACO expansion plan. Management said external growth would likely be signed in 2027 with a 12- to 18-month implementation timeline, implying 2028 impact, and that it would be tied to full-risk arrangements rather than care coordination fees. On cost trends, management said the first half developed favorably into the low 6% range, while Q3 ran in the low 7% range with limited paid-claims visibility. On ACOs, management said the business already has about half of its partners involved, sees continued embedded growth opportunity, and expects around 160,000 ACO members in 2027 versus about 110,000 today.
The company showed clear operating leverage this quarter, with revenue, EBITDA, and medical margin all outperforming expectations. Management believes clinical pathways, better risk adjustment, and ACO expansion can continue to drive results into 2027, while cash generation is improving enough to raise the year-end cash outlook to at least $175 million.
Medicare Advantage membership remains down year over year, reflecting prior market exits and a measured growth approach. Management also cautioned that Q4 is typically the lowest-earning quarter and still assumes 7% cost trend there, while 2027 contracting gains are expected to be more modest than 2026 because fewer contracts are being repriced.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.8%
- Shares Outstanding
- 16.80M
- Float Shares
- 11.72M
of shares held by institutions
193 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 18.32M | ▼ 5.97M |
| Clayton, Dubilier & Rice, LLC | 4.00M | 0 |
| Morgan Stanley | 2.10M | ▲ 86.75K |
| North Peak Capital Management, LLC | 1.58M | ▲ 99.80K |
| Blackrock, Inc. | 1.31M | ▲ 162.73K |
| Two Sigma Advisers, LP | 1.11M | ▲ 1.11M |
| Aqr Capital Management LLC | 678.38K | ▼ 14.16K |
| Goldman Sachs Group Inc | 655.93K | ▼ 30.86K |
| Vanguard Capital Management LLC | 521.98K | ▼ 3.34K |
| Durable Capital Partners LP | 440.64K | 0 |
| Geode Capital Management, LLC | 334.89K | ▲ 20.72K |
| State Street Corp | 326.16K | ▲ 46.03K |
Held by 232 ETFs
Biggest fund positions in AGL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 16, 26 | Gertsch Timothy | other | 17 |
| Aug 1, 26 | Zamore Denise | other | 37 |
| Jul 1, 26 | Schwaneke Jeffrey A. | other | 2,311 |
| Jun 1, 26 | Zamore Denise | other | 485 |
| Jun 2, 26 | Wulf John William | other | 2,133 |
| Jun 2, 26 | WILLIAMS RONALD A | other | 2,133 |
| Jun 2, 26 | McLoughlin Karen | other | 2,133 |
| Jun 2, 26 | MCKENZIE DIANA | other | 2,133 |
| Jun 2, 26 | Mansukani Sharad | other | 2,133 |
| Jun 2, 26 | Battaglia Silvana | other | 2,133 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AGL coverage
Recent articles, reports, and earnings notes.
No research on AGL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGL report →Best Momentum Stocks to Buy for November 19th
zacks.com · Nov 19
New Strong Buy Stocks for November 19th
zacks.com · Nov 19
agilon health, inc. (AGL) Driving Performance at Scale: Technology-Enabled Clinical and Quality Programs Transcript
seekingalpha.com · Nov 17
agilon health: Same Doctors, Higher Risk Scores, Thinner Reserve
seekingalpha.com · Nov 17
Agilon Health (AGL) Is Up 2.00% in One Week: What You Should Know
zacks.com · Nov 16
Best Momentum Stocks to Buy for November 16th
zacks.com · Nov 16
Fast-paced Momentum Stock Agilon (AGL) Is Still Trading at a Bargain
zacks.com · Nov 16
New Strong Buy Stocks for November 16th
zacks.com · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.